尔康制药
(300267)
| 流通市值：50.64亿 | | | 总市值：73.43亿 |
| 流通股本：14.22亿 | | | 总股本：20.63亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,006,423,651.81 | 681,881,688.38 | 353,547,866.17 | 1,139,612,276.29 |
| 营业收入 | 1,006,423,651.81 | 681,881,688.38 | 353,547,866.17 | 1,139,612,276.29 |
| 二、营业总成本 | 985,154,942.51 | 656,655,615.53 | 338,072,474.37 | 1,213,768,146.03 |
| 营业成本 | 730,971,679.11 | 494,458,519.8 | 261,148,226.49 | 825,958,465.34 |
| 税金及附加 | 10,769,674.33 | 7,146,069.57 | 3,493,070.86 | 16,670,464.22 |
| 销售费用 | 42,686,764.62 | 23,743,816.68 | 8,128,608.81 | 99,644,171.46 |
| 管理费用 | 166,946,302.81 | 109,942,828.09 | 54,188,849.7 | 226,034,547.54 |
| 研发费用 | 30,243,874.28 | 19,936,622.82 | 9,935,801.85 | 45,170,389.39 |
| 财务费用 | 3,536,647.36 | 1,427,758.57 | 1,177,916.66 | 290,108.08 |
| 其中:利息费用 | 8,500,831.33 | 4,602,930.58 | 2,731,240.92 | 9,331,116.15 |
| 其中:利息收入 | 4,259,238.33 | 2,463,701.99 | 933,387.34 | 4,734,525.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -4,450,541.22 | -2,979,757.81 | - | 419,800 |
| 加:投资收益 | 3,493,479.34 | 2,896,732.49 | 2,661,106.84 | -55,831,057.55 |
| 资产处置收益 | 329,127.92 | 323,099.98 | -42,801.59 | 198,252.71 |
| 资产减值损失(新) | -1,044,096.3 | -1,583,963.93 | -181,352.27 | -261,206,368.61 |
| 信用减值损失(新) | 3,986,929.68 | 3,492,381.11 | 5,671,076.98 | 70,429.94 |
| 其他收益 | 10,685,366.8 | 4,737,580.57 | 2,644,876.88 | 19,896,736.03 |
| 四、营业利润 | 34,268,975.52 | 32,112,145.26 | 26,228,298.64 | -370,608,077.22 |
| 加:营业外收入 | 941,328.18 | 801,696.37 | 479,839.6 | 831,282.11 |
| 减:营业外支出 | 4,460,141.02 | 860,362.25 | 121,253.7 | 18,341,011.16 |
| 五、利润总额 | 30,750,162.68 | 32,053,479.38 | 26,586,884.54 | -388,117,806.27 |
| 减:所得税费用 | 3,639,448.23 | 3,242,921.84 | 2,644,841.35 | 4,509,066.4 |
| 六、净利润 | 27,110,714.45 | 28,810,557.54 | 23,942,043.19 | -392,626,872.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 27,110,714.45 | 28,810,557.54 | 23,942,043.19 | -392,626,872.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 39,575,891.64 | 37,634,642.58 | 28,112,585.22 | -373,371,435.91 |
| 少数股东损益 | -12,465,177.19 | -8,824,085.04 | -4,170,542.03 | -19,255,436.76 |
| 扣除非经常损益后的净利润 | 35,230,318.55 | 33,018,734.45 | 24,709,317.94 | -368,820,598.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.02 | 0.01 | -0.18 |
| (二)稀释每股收益 | 0.02 | 0.02 | 0.01 | -0.18 |
| 八、其他综合收益 | -17,720,724.55 | -15,845,203.45 | -11,550,621.21 | -15,464,320.82 |
| 归属于母公司股东的其他综合收益 | -17,860,457.67 | -15,808,076.31 | -11,467,886.08 | -15,519,629.2 |
| 九、综合收益总额 | 9,389,989.9 | 12,965,354.09 | 12,391,421.98 | -408,091,193.49 |
| 归属于母公司股东的综合收益总额 | 21,715,433.97 | 21,826,566.27 | 16,644,699.14 | -388,891,065.11 |
| 归属于少数股东的综合收益总额 | -12,325,444.07 | -8,861,212.18 | -4,253,277.16 | -19,200,128.38 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-23 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |